Age-related Macular Degeneration (AMD)

The following highlights relevant clinical data on age-related macular degeneration:

• Main cause of severe & irreversible blindness in individuals over 50 worldwide.¹
• Time to treatment is critical for prognosis:  Delaying therapy by 2-3 months results in significant loss of visual acuity.²
• Common genetic variants and environmental risk factors combine to affect risk of disease.³

Why Navigenics?

With the Navigenics AMD genotyping you have the potential to identify the 5% of people estimated to have 3.5 or more times (with a maximum of 65 times) the average AMD risk ⁴

Clinical Relevance

	Eye Exam	Navigenics Genotyping: AMD
Focus of test	Diagnosis	Prevention
Timing	After symptoms	Before symptoms
Frequency	Annual test with low compliance (<40% for US adults)5

The same test covers 26 other conditions, providing you with genetic risk information that informs clinical decision-making and preventative guidance.

Why now?

By knowing your patient’s genetic risk you can promote lifestyle changes and diagnostic measures such as OCT to impact macular degeneration as early as possible.

Target your preventative medical practices by incorporating personal genetic risk today.
 

1. Ambati. Surv Ophthalmol 48:257. 2003
2. Arias. Eye 23:326. 2009
3. Seddon. Invest Ophthalmol Vis Sci 50:2044. 2009
4. Based on Navigenics composite genetic risk calculations using a HapMap reference population. For more information on these calculations, including our mathematical models and curation practices, please see “The Science Behind the Navigenics Service,” a white paper found at http://www.navigenics.com/static/pdf/Navigenics-TheScience.pdf.
5. Zhang. Arch Ophthalmol 125:411. 2007